Journal article
Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis
Abstract
Correspondence on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis [Lanctôt KL et al., Curr Med Res Opin 2009; 24: 3223-37; doi:10.1185/03007990802484234]
Authors
L. RJ; L. LK; Bosco P; Charles H; Aaron C; Jean-Eric T
Journal
Current Medical Research and Opinion, Vol. 25, No. 7, pp. 1631–1633
Publisher
Taylor & Francis
Publication Date
July 1, 2009
DOI
10.1185/03007990902993415
ISSN
0300-7995